Search - tctmd.com

Displaying 61 - 80 of 89

Sort: Relevancy | Date

Presentation TCT 2023

Optimal Antithrombotic Strategies in MCS Use

Presenter: Mirvat Alasnag

October 26, 2023

Presentation TCT 2023

Con: Favorable Data Is Lacking on MCS in AMI Cardiogenic Shock (Randomized Data Are Needed)

Presenter: Sanjit Jolly

October 24, 2023

Presentation TCT 2023

Pro: Most Patients With AMI Cardiogenic Shock Should Get MCS (Randomization Is Unethical)

Presenter: William O'Neill

October 24, 2023

Presentation TCT 2023

TCT 740: Multidisciplinary Team Approach to Reducing Vascular Complications in MCS Impella Support Patients

Presenter: Haroon Faraz

October 24, 2023

Presentation TCT 2023

My Top 5 Most Critical Clinical and Technology Needs in Temporary MCS

Presenter: Nicolas Van Mieghem

October 23, 2023

Presentation TCT 2022

Distal Limb Protection During MCS: Balancing Risk and Benefit

Presenter: Jose Wiley

September 19, 2022

Presentation TCT 2022

Update From the AHA Expert Consensus Document: When/How to De-escalate MCS

Presenter: Ajar Kochar

September 19, 2022

Presentation TCT 2022

Update From the AHA Expert Consensus Document: When/How to Escalate MCS

Presenter: Gregory Serrao

September 19, 2022

Presentation TCT 2022

Is There a Role for MCS in Massive PE and Which Modality?

Presenter: Andrew Klein

September 19, 2022

Presentation TCT 2022

Percutaneous MCS Support for PCI in Surgically Ineligible Patients: Preliminary Results from Optimum

Presenter: Adam Salisbury

September 18, 2022

Presentation TCT 2022

MCS Initiation - Fuel Injection or Plug In the Pump?: Pharmacological vs. Mechanical Support

Presenter: Jeffrey Shih

September 16, 2022

Presentation TCT 2022

Impella Regret: Case-based Advancement in MCS Decision-Making and Execution

Presenter: Nathan Masterson

September 16, 2022

News Conference News TCT 2021

Mortality High in Patients With STEMI, COVID-19 on Hemodynamic Support

Caitlin E. Cox

November 11, 2021

Presentation TCT 2021

The Role of MCS Assisted With Catheter Directed Therapy

Presenter: Sanjum Sethi

November 06, 2021

Presentation TCT 2021

Con: Is Impella CP the First-line MCS of Choice for Acute MI and Cardiogenic Shock?

Presenter: Sandeep Nathan

November 05, 2021

Presentation TCT 2021

Pro: Is Impella CP the First-line MCS of Choice for Acute MI and Cardiogenic Shock?

Presenter: Arthur Reshad Garan

November 05, 2021

News Conference News TCT 2020

Trickier Patients, Fewer Adverse Events in High-risk PCI: Impella PROTECT III Registry

Caitlin E. Cox

October 18, 2020

Presentation TCT 2020

What Clinical Trials Are Needed to Support MCS in the Modern Era?

Presenter: Gregg Stone

October 16, 2020

Presentation TCT 2020

Regulatory Viewpoints on MCS Device Approval

Presenter: Meir Shinnar

October 16, 2020

Presentation TCT 2020

The Role of MCS Is Anything but Proven!

Presenter: Sunil Rao

October 14, 2020

Advertisement

Optimal Antithrombotic Strategies in MCS Use

Con: Favorable Data Is Lacking on MCS in AMI Cardiogenic Shock (Randomized Data Are Needed)

Pro: Most Patients With AMI Cardiogenic Shock Should Get MCS (Randomization Is Unethical)

TCT 740: Multidisciplinary Team Approach to Reducing Vascular Complications in MCS Impella Support Patients

My Top 5 Most Critical Clinical and Technology Needs in Temporary MCS

Distal Limb Protection During MCS: Balancing Risk and Benefit

Update From the AHA Expert Consensus Document: When/How to De-escalate MCS

Update From the AHA Expert Consensus Document: When/How to Escalate MCS

Is There a Role for MCS in Massive PE and Which Modality?

Percutaneous MCS Support for PCI in Surgically Ineligible Patients: Preliminary Results from Optimum

MCS Initiation - Fuel Injection or Plug In the Pump?: Pharmacological vs. Mechanical Support

Impella Regret: Case-based Advancement in MCS Decision-Making and Execution

Mortality High in Patients With STEMI, COVID-19 on Hemodynamic Support

The Role of MCS Assisted With Catheter Directed Therapy

Con: Is Impella CP the First-line MCS of Choice for Acute MI and Cardiogenic Shock?

Pro: Is Impella CP the First-line MCS of Choice for Acute MI and Cardiogenic Shock?

Trickier Patients, Fewer Adverse Events in High-risk PCI: Impella PROTECT III Registry

What Clinical Trials Are Needed to Support MCS in the Modern Era?

Regulatory Viewpoints on MCS Device Approval

The Role of MCS Is Anything but Proven!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content